Vyepti (eptinezumab), a migraine treatment developed by Denmark-based biopharmaceutical company H. Lundbeck A/S (OTCMKTS: HLBBF), has been introduced at Sun Yat-sen Memorial Hospital, Sun Yat-sen University, facilitated by the “Hong Kong-Macau Drug and Device Access” policy. This policy, part of the broader Greater Bay Area initiative, enables patients to access medicines available in Hong Kong, Macau, and various cities within Guangzhou.
Eptinezumab received approval from the US FDA in February 2020 for the preventive treatment of migraine in adults. It stands as the first and only FDA-approved CGRP-targeting monoclonal antibody for migraine prevention through intravenous injection. With its rapid onset, clear therapeutic benefits, and minimal side effects, eptinezumab is administered quarterly and has been shown to enhance patient compliance and reduce the overall disease burden. The drug was launched in the Boao Lecheng International Medical Tourism Zone in November 2022.- Flcube.com
